Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739454 | 0.94 | CA4 (0.46) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL8844249 | 0.94 | CA4 (0.52) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Silver SCHEMBL6739447 | 0.94 | CA4 (0.46) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Water SCHEMBL14109454 | 0.92 | CA4 (0.44) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL666362 | 0.77 | CA4 (0.43) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL9768490 | 0.76 | ALDH1A1 (0.38) | CA4HMGCRCHRM1TBXA2RADRA1A | |
| T-Butylacetic Acid SCHEMBL11218671 | 0.71 | — | — | |
| SCHEMBL10887232 | 0.71 | CA4 (0.43) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| Silver SCHEMBL6733904 | 0.71 | CA4 (0.43) | CA4FFAR3HDAC3HDAC1HDAC2 | |
| T-Butylacetic Acid SCHEMBL4319302 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | CA4 1926/4885FFAR3 2513/4885HDAC3 1537/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | CA4 1926/4885FFAR3 2513/4885HDAC3 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.